GEN İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GEN) and Santhera Pharmaceuticals, based in Switzerland, have signed an exclusive distribution agreement.
Under the agreement, GEN will be the exclusive distributor in Türkiye for AGAMREE® (vamorolone), a product used in the treatment of Duchenne Muscular Dystrophy (DMD) in patients aged four years and older.
Supply and sales of the drug are expected to begin in the first half of 2026.
Upon the agreement coming into effect, GEN will follow the necessary procedures for the drug to be added to the foreign drug list of the Turkish Ministry of Health, and once the process is complete, the drug will be supplied and sold in Türkiye under the Named Patient Program (NPP).
